A U.S. Dividend Stock With 35% Upside Potential

Search no further than AbbVie Inc. (NYSE:ABBV) for a discounted company with double-digit growth potential for price appreciation and dividend growth.

| More on:
The Motley Fool

It costs about 30% more to buy U.S. stocks because of the strong U.S. dollar compared to the weak Canadian dollar. The interest rate in the United States is rising steadily, and its economy is viewed as stronger than ours, so it might still be worth it to buy U.S. stocks.

With so many U.S. dividend stocks, which ones should you consider? Again, because of the pricey foreign exchange, it makes sense to look for companies that are priced at a discount. I think dividend stocks have added safety because a portion of their earnings are returned to shareholders regularly.

I happened to come across an A-grade U.S. dividend stock that is discounted by 26%: AbbVie Inc. (NYSE:ABBV).

The business

AbbVie is a research-based biopharmaceutical company with a focus on immunology and oncology. It has an S&P credit rating of A, and it employs more than 28,000 people around the world and markets medicines in more than 170 countries. Last year it generated US$22.8 billion in sales.

AbbVie was spun off from Abbott Laboratories in 2013. Since then, AbbVie has increased its earnings per share (EPS) on average by 16.6% per year. This growth supported its dividend increase of 12.5% on average per year. At about US$55, it yields 4.1% with a payout ratio of about 53% based on its 2015 earnings per share.

Concerns and future growth

Interested investors should note that last year AbbVie generated 58% of its sales from one drug, Humira, which may partly explain why the shares are discounted.

However, so far the company continues to deliver strong results. Additionally, its cancer drug, Imbruvica, also contributes meaningfully to its sales. By 2020, AbbVie expects total sales to reach US$37 billion, of which Humira sales would make up more than US$18 billion and Imbruvica sales would make up about US$5 billion.

AbbVie’s Duodopa/Duopa drug, a leader in the treatment of advanced Parkinson’s Disease, can also reach blockbuster status. And AbbVie estimates the drug could generate sales of more than $1 billion by 2020.

On top of all that, AbbVie could potentially launch more than 20 new products through 2020, which would help support the company’s forecast of double-digit EPS growth on average through 2020. For 2016, AbbVie anticipates EPS to increase about 17%.


AbbVie is priced at 12.5 times its earnings and is discounted by about 26% for the company’s 17% EPS growth forecast. So, it has an upside potential of 35%.

If you have U.S. dollars lying around or have a long-term view in investing, AbbVie should make a nice addition to your portfolio for double-digit price appreciation and dividend growth potential, while you get a decent 4% yield to start.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Kay Ng has no position in any of the stocks mentioned.

More on Dividend Stocks

Payday ringed on a calendar
Dividend Stocks

Portfolio Payday: 3 TSX Dividend Stocks That Pay Monthly

Investors can expect to earn monthly dividend income for life by adding these three TSX stock to their portfolios.

Read more »

A plant grows from coins.
Dividend Stocks

3 Cheap Canadian Stocks That Offer 7% Dividend Yields

Retirees looking to build pension portfolios have an opportunity to buy great TSX dividend-growth stocks at discounted prices.

Read more »

dividends grow over time
Dividend Stocks

2 Dividend Stocks That Can Generate $2,000 in Passive Income by 2025

Investing in high-dividend stocks such as Whitecap can help you generate $2,000 in annual passive income by 2025.

Read more »

edit Woman calculating figures next to a laptop
Dividend Stocks

Should You Invest in BCE Stock for its Dividend?

BCE stock is not yet out of the woods. But this article could change your perspective about the stock and…

Read more »

sale discount best price
Dividend Stocks

Bargain Hunting for Dividends: 3 High-Yield Stocks Haven’t Been This Cheap in Years

Enbridge (TSX:ENB) stock's key enterprise value multiple reached a new multi-year low recently. BCE remains a high-yield dividend play while…

Read more »

Various Canadian dollars in gray pants pocket
Dividend Stocks

Cash in Your Pocket: 3 TSX Dividend Stocks That Pay Out Monthly

Bolster your monthly income with these three dividends stocks that act like regular paycheques.

Read more »

A plant grows from coins.
Dividend Stocks

Beat the TSX Index With These Cash-Gushing Dividend Stocks

These cash flow-rich stocks are more likely to gush passive dividend income streams long into the future.

Read more »

Golden crown on a red velvet background
Dividend Stocks

Here Are My Top 5 Dividend Aristocrats to Buy Right Now

Canadian National Railway (TSX:CNR) is a Dividend Aristocrat with 27 years of dividend growth.

Read more »